Glioblastoma | Norton Healthcare

Indication: Glioblastoma

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Sub-indication: CNS Cancer

Study Type: Drug Study

Principal Investigator: Kaylyn Sinicrope, M.D.
Norton Brain Tumor Center

Sponsor: Sponsor: Denovo Biopharma LLC

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.